Exhorbitant price of patented life-saving medicines: Kerala HC reserves verdict
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
The has reserved its verdict in a suo motu case concerning the exorbitant prices of patented life-saving medicines, specifically breast cancer drugs like Ribociclib. The case, initially filed by a patient seeking government intervention to acquire the patent and lower costs, highlights the tension between intellectual property rights and the fundamental right to health. The court is exploring legal mechanisms, including compulsory licensing, to ensure affordability of essential medications.
UPSC Perspectives
Polity
This case underscores the vital connection between the enshrined in of the Constitution and access to affordable healthcare. The 's suo motu intervention (acting on its own accord in public interest) demonstrates judicial activism aimed at protecting this fundamental right. UPSC aspirants should analyze this in the context of the state's obligation to ensure public health, as outlined in the (), which mandates the state to improve public health. The court's consideration of forcing the government to take over the patent touches upon the balance between individual rights (patent holder's property rights) and public welfare. Exam questions could focus on how the judiciary interprets to mandate state action in ensuring the availability and affordability of life-saving medical treatments, especially when intellectual property laws create barriers to access.
Economic
The core economic issue here is the tension between intellectual property rights (IPR) and public health accessibility. The high cost of patented drugs like Ribociclib restricts access for many patients, highlighting a market failure where critical needs are unmet due to monopoly pricing. The legal framework relevant here is the , specifically the provisions regarding compulsory licensing ( and ). Compulsory licensing allows the government to authorize a third party to manufacture a patented product without the consent of the patent owner, usually during a public health emergency or when the drug is unaffordable. The also affirms the right of member states to protect public health and promote access to medicines. In the Mains exam, you might be asked to evaluate the effectiveness of compulsory licensing in India, discussing past instances (like the Nexavar case) and the ongoing debate over balancing the need to incentivize pharmaceutical innovation with the imperative of providing affordable healthcare.
Governance
The situation highlights the complex governance challenges in regulating pharmaceutical pricing in India. While the (NPPA) regulates the prices of essential medicines listed under the (NLEM), many newer, patented, and expensive life-saving drugs often fall outside this purview. The government's reluctance or delay in invoking compulsory licensing or price caps on such critical drugs raises questions about the prioritization of public health over corporate interests. Aspirants should consider the role of regulatory bodies and the need for policy reforms to address the affordability of patented medicines. This could involve exploring alternative mechanisms like patent pools, voluntary licensing agreements, or expanding the scope of the (DPCO). A relevant Mains question could ask for a critical assessment of India's current drug pricing policy and suggest measures to ensure equitable access to advanced life-saving treatments.